Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
Autologous hematopoietic stem cell transplantation (AHSCT) is established as a standard of care for diseases ranging from hematological malignancies to other neoplastic pathologies and severe immunological deficiencies. In April 1995, our group performed the first AHSCT in progressive multiple scler...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2019/5840286 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473139086458880 |
|---|---|
| author | Maria Gavriilaki Ioanna Sakellari Eleni Gavriilaki Vasilios K. Kimiskidis Achilles Anagnostopoulos |
| author_facet | Maria Gavriilaki Ioanna Sakellari Eleni Gavriilaki Vasilios K. Kimiskidis Achilles Anagnostopoulos |
| author_sort | Maria Gavriilaki |
| collection | DOAJ |
| description | Autologous hematopoietic stem cell transplantation (AHSCT) is established as a standard of care for diseases ranging from hematological malignancies to other neoplastic pathologies and severe immunological deficiencies. In April 1995, our group performed the first AHSCT in progressive multiple sclerosis (MS). Since then, a plethora of studies have been published with encouraging but controversial results. Major challenges in the field include appropriate patient selection, improvements in AHSCT procedure, and timing of this treatment modality. Beyond AHSCT, several new intravenous or oral agents have been developed and approved over the last 20 years in MS. The emergence of multiple effective therapies for MS has created a challenging scenario for both treating physicians and patients. Novel cell-based therapies other than AHSCT are also currently investigated in MS patients with promising results. Our review is aimed at summarizing state-of-the-art knowledge on basic principles and results of AHSCT in MS and its role compared to novel agents. |
| format | Article |
| id | doaj-art-d9292c4bdf0d44f88948fc7c03e1a7bb |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-d9292c4bdf0d44f88948fc7c03e1a7bb2025-08-20T03:24:16ZengWileyStem Cells International1687-966X1687-96782019-01-01201910.1155/2019/58402865840286Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel AgentsMaria Gavriilaki0Ioanna Sakellari1Eleni Gavriilaki2Vasilios K. Kimiskidis3Achilles Anagnostopoulos4Postgraduate Course, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceHematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, GreeceHematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, GreecePostgraduate Course, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceHematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, GreeceAutologous hematopoietic stem cell transplantation (AHSCT) is established as a standard of care for diseases ranging from hematological malignancies to other neoplastic pathologies and severe immunological deficiencies. In April 1995, our group performed the first AHSCT in progressive multiple sclerosis (MS). Since then, a plethora of studies have been published with encouraging but controversial results. Major challenges in the field include appropriate patient selection, improvements in AHSCT procedure, and timing of this treatment modality. Beyond AHSCT, several new intravenous or oral agents have been developed and approved over the last 20 years in MS. The emergence of multiple effective therapies for MS has created a challenging scenario for both treating physicians and patients. Novel cell-based therapies other than AHSCT are also currently investigated in MS patients with promising results. Our review is aimed at summarizing state-of-the-art knowledge on basic principles and results of AHSCT in MS and its role compared to novel agents.http://dx.doi.org/10.1155/2019/5840286 |
| spellingShingle | Maria Gavriilaki Ioanna Sakellari Eleni Gavriilaki Vasilios K. Kimiskidis Achilles Anagnostopoulos Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents Stem Cells International |
| title | Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents |
| title_full | Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents |
| title_fullStr | Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents |
| title_full_unstemmed | Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents |
| title_short | Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents |
| title_sort | autologous hematopoietic cell transplantation in multiple sclerosis changing paradigms in the era of novel agents |
| url | http://dx.doi.org/10.1155/2019/5840286 |
| work_keys_str_mv | AT mariagavriilaki autologoushematopoieticcelltransplantationinmultiplesclerosischangingparadigmsintheeraofnovelagents AT ioannasakellari autologoushematopoieticcelltransplantationinmultiplesclerosischangingparadigmsintheeraofnovelagents AT elenigavriilaki autologoushematopoieticcelltransplantationinmultiplesclerosischangingparadigmsintheeraofnovelagents AT vasilioskkimiskidis autologoushematopoieticcelltransplantationinmultiplesclerosischangingparadigmsintheeraofnovelagents AT achillesanagnostopoulos autologoushematopoieticcelltransplantationinmultiplesclerosischangingparadigmsintheeraofnovelagents |